The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Mesenchymal stem cells: immune evasive, not immune privileged
Open accessAbstract
The diverse immunomodulatory properties of mesenchymal stem/stromal cells (MSCs) may be exploited for treatment of a multitude of inflammatory conditions. MSCs have long been reported to be hypoimmunogenic or 'immune privileged'; this property is thought to enable MSC transplantation across major histocompatibility barriers and the creation of off-the-shelf therapies consisting of MSCs grown in culture. However, recent studies describing generation of antibodies against and immune rejection of allogeneic donor MSCs suggest that MSCs may not actually be immune privileged. Nevertheless, whether rejection of donor MSCs influences the efficacy of allogeneic MSC therapies is not known, and no definitive clinical advantage of autologous MSCs over allogeneic MSCs has been demonstrated to date. Although MSCs may exert therapeutic function through a brief 'hit and run' mechanism, protecting MSCs from immune detection and prolonging their persistence in vivo may improve clinical outcomes and prevent patient sensitization toward donor antigens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Caplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Cell Surface Engineering by a Modified Staudinger Reaction
Saxon, E., & Bertozzi, C. R. (2000) · Science · doi:10.1126/science.287.5460.2007 · Cited by 2,460
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00769-x · Cited by 2,295
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Immunomodulatory properties of mesenchymal stromal cells
Nauta, A. J., & Fibbe, W. E. (2007) · Blood · doi:10.1182/blood-2007-02-069716 · Cited by 1,788
Immunosuppressive effects of apoptotic cells
Voll, R. E., Herrmann, M., Roth, E. A., Stach, C., Kalden, J. R., & Girkontaite, I. (1997) · Nature · doi:10.1038/37022 · Cited by 1,787
Cited by
Molecular principles of metastasis: a hallmark of cancer revisited
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0134-x · Cited by 2,379
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
“Indeed, the notion of MSC being immunoevasive and not immune privileged has been proposed(Ankrum et al., 2014).”
BackgroundApplying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
“Generally, the original MSCs are believed to have low immunogenicity [16].”
BackgroundWeiss, A. R. R., & Dahlke, M. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01191 · Cited by 695
Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation
Galleu, A., Riffo-Vasquez, Y., Trento, C., Lomas, C., Dolcetti, L., Cheung, T. S., von Bonin, M., Barbieri, L., Halai, K., Ward, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7828 · Cited by 646
Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05034-x · Cited by 640
Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies
Noronha, N. D. C., Mizukami, A., Caliári-Oliveira, C., Cominal, J. G., Rocha, J. L. M., Covas, D. T., Swiech, K., & Malmegrim, K. C. R. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1224-y · Cited by 623
Vega, A., Martín-Ferrero, M. A., Del Canto, F., Alberca, M., García, V., Munar, A., Orozco, L., Soler, R., Fuertes, J. J., Huguet, M., et al. (2015) · Transplantation · doi:10.1097/tp.0000000000000678 · Cited by 571
Challenges and Controversies in Human Mesenchymal Stem Cell Therapy
Lukomska, B., Stanaszek, L., Zuba-Surma, E., Legosz, P., Sarzynska, S., & Drela, K. (2019) · Stem Cells International · doi:10.1155/2019/9628536 · Cited by 550
Spheroid Culture of Mesenchymal Stem Cells
Cesarz, Z., & Tamama, K. (2016) · Stem Cells International · doi:10.1155/2016/9176357 · Cited by 475
Moll, G., Ankrum, J. A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D., Geissler, S., & Reinke, P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.006 · Cited by 440
Self-citationEngineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M., & Veiseh, O. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 439
Preconditioning influences mesenchymal stem cell properties in vitro and in vivo
Hu, C., & Li, L. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13492 · Cited by 438
Immunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications
Castro-Manrreza, M. E., & Montesinos, J. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/394917 · Cited by 399
Moll, G., Alm, J. J., Davies, L. C., von Bahr, L., Heldring, N., Stenbeck-Funke, L., Hamad, O. A., Hinsch, R., Ignatowicz, L., Locke, M., et al. (2014) · Stem Cells · doi:10.1002/stem.1729 · Cited by 381
Chronic Diabetic Wounds and Their Treatment with Skin Substitutes
Holl, J., Kowalewski, C., Zimek, Z., Fiedor, P., Kaminski, A., Oldak, T., Moniuszko, M., & Eljaszewicz, A. (2021) · Cells · doi:10.3390/cells10030655 · Cited by 351
Marquez-Curtis, L. A., Janowska-Wieczorek, A., McGann, L. E., & Elliott, J. A. W. (2015) · Cryobiology · doi:10.1016/j.cryobiol.2015.07.003 · Cited by 346
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
“Furthermore, several studies have reported the ability of MSCs to polarize T cells towards immunosuppressive regulatory phenotype, dampening inflammation [11, 35].”
BackgroundManufacturing of primed mesenchymal stromal cells for therapy
Yin, J. Q., Zhu, J., & Ankrum, J. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0325-8 · Cited by 343
Self-citationHydrogel as a bioactive material to regulate stem cell fate
Tsou, Y.-H., Khoneisser, J., Huang, P.-C., & Xu, X. (2016) · Bioactive Materials · doi:10.1016/j.bioactmat.2016.05.001 · Cited by 317
Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application
Caplan, H., Olson, S. D., Kumar, A., George, M., Prabhakara, K. S., Wenzel, P., Bedi, S., Toledano-Furman, N. E., Triolo, F., Kamhieh-Milz, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01645 · Cited by 306
Mattar, P., & Bieback, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00560 · Cited by 300
Shigemoto-Kuroda, T., Oh, J. Y., Kim, D.-K., Jeong, H. J., Park, S. Y., Lee, H. J., Park, J. W., Kim, T. W., An, S. Y., Prockop, D. J., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.04.008 · Cited by 296
Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-γ
Kim, D. S., Jang, I. K., Lee, M. W., Ko, Y. J., Lee, D.-H., Lee, J. W., Sung, K. W., Koo, H. H., & Yoo, K. H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.002 · Cited by 287
Mesenchymal stem cells: Amazing remedies for bone and cartilage defects
Kangari, P., Talaei-Khozani, T., Razeghian-Jahromi, I., & Razmkhah, M. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02001-1 · Cited by 286
Wolf, M., Poupardin, R. W., Ebner‐Peking, P., Andrade, A. C., Blöchl, C., Obermayer, A., Gomes, F. G., Vari, B., Maeding, N., Eminger, E., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12207 · Cited by 284
Zhao, T., Wu, W., Sui, L., Huang, Q., Nan, Y., Liu, J., & Ai, K. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.06.006 · Cited by 267
Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis
Jiang, Y., Zhang, P., Zhang, X., Lv, L., & Zhou, Y. (2021) · Cell Proliferation · doi:10.1111/cpr.12956 · Cited by 265
Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis
Maacha, S., Sidahmed, H., Jacob, S., Gentilcore, G., Calzone, R., Grivel, J.-C., & Cugno, C. (2020) · Stem Cells International · doi:10.1155/2020/4356359 · Cited by 259
“While it was initially conceived that MSCs exerted their therapeutic effects by migrating to targeted sites of injury and actively contributed to tissue repair and regeneration, it is now increasingly acknowledged that MSCs do not typically engraft after transplantation, due to the phenomena of lung sequestration and…”
BackgroundAdult Stem Cells for Bone Regeneration and Repair
Iaquinta, M. R., Mazzoni, E., Bononi, I., Rotondo, J. C., Mazziotta, C., Montesi, M., Sprio, S., Tampieri, A., Tognon, M., & Martini, F. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00268 · Cited by 259
Quiescent tissue stem cells evade immune surveillance
Agudo, J., Park, E. S., Rose, S. A., Alibo, E., Sweeney, R., Dhainaut, M., Kobayashi, K. S., Sachidanandam, R., Baccarini, A., Merad, M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.02.001 · Cited by 244
The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke
Cunningham, C. J., Redondo-Castro, E., & Allan, S. M. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18776802 · Cited by 242
Non-genetic engineering of cells for drug delivery and cell-based therapy
Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.003 · Cited by 225
Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases
Volkman, R., & Offen, D. (2017) · Stem Cells · doi:10.1002/stem.2651 · Cited by 222
Adipose-derived stem cells secretome and its potential application in “stem cell-free therapy”
Trzyna, A., & Banaś-Ząbczyk, A. (2021) · Biomolecules · doi:10.3390/biom11060878 · Cited by 201
García-Bernal, D., García-Arranz, M., Yáñez, R. M., Hervás-Salcedo, R., Cortés, A., Fernández-García, M., Hernando-Rodríguez, M., Quintana-Bustamante, Ó., Bueren, J. A., García-Olmo, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650664 · Cited by 138
Mesenchymal stem cell-derived exosome: A tumor regulator and carrier for targeted tumor therapy
Zhang, F., Guo, J., Zhang, Z., Qian, Y., Wang, G., Duan, M., Zhao, H., Yang, Z., & Jiang, X. (2022) · Cancer Letters · doi:10.1016/j.canlet.2021.11.015 · Cited by 127
Andrzejewska, A., Catar, R., Schoon, J., Qazi, T. H., Sass, F. A., Jacobi, D., Blankenstein, A., Reinke, S., Krüger, D., Streitz, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02474 · Cited by 89
“Both, autologous and allogeneic BMSC therapies are widely studied, and it is not clear yet which approach will be favored for specific treatment indications (87).”
BackgroundXia, Y., Zhu, J., Yang, R., Wang, H., Li, Y., & Fu, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1141601 · Cited by 87
Mesenchymal stem cell immunomodulation: in pursuit of controlling COVID-19 related cytokine storm
Song, N., Wakimoto, H., Rossignoli, F., Bhere, D., Ciccocioppo, R., Chen, K.-S., Khalsa, J. K., Mastrolia, I., Samarelli, A. V., Dominici, M., et al. (2021) · Stem Cells · doi:10.1002/stem.3354 · Cited by 62
Jia, X.-H., Feng, G.-W., Wang, Z.-L., Du, Y., Shen, C., Hui, H., Peng, D., Li, Z.-J., Kong, D.-L., & Tian, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8064 · Cited by 62
Srinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.11.009 · Cited by 44
Chen, X., Zheng, J., Yin, L., Li, Y., & Liu, H. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-04846-1 · Cited by 34
Matsumoto, T., Sato, Y., Kobayashi, T., Suzuki, K., Kimura, A., Soma, T., Ito, E., Kikuchi, T., Kobayashi, S., Harato, K., et al. (2021) · The American Journal of Sports Medicine · doi:10.1177/03635465211041582 · Cited by 32
Universal or Personalized Mesenchymal Stem Cell Therapies: Impact of Age, Sex, and Biological Source
Carp, D. M., & Liang, Y. (2022) · Cells · doi:10.3390/cells11132077 · Cited by 29
“MSCs have long been considered hypoimmunogenic, which can potentially enable MSC transplantation across major histocompatibility barriers and cell expansion in culture prior to transfer [1,11].”
BackgroundMesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04127-y · Cited by 29
Ehlen, Q. T., Costello, J. P., Mirsky, N. A., Slavin, B. V., Parra, M., Ptashnik, A., Nayak, V. V., Coelho, P. G., & Witek, L. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c01279 · Cited by 29
Apelin/APJ system: A novel therapeutic target for locomotor system diseases
Luo, J., Liu, W., Feng, F., & Chen, L. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174286 · Cited by 28
Lu, W., Xu, J., Dong, S., Xie, G., Yang, S., Huangfu, X., Li, X., Zhang, Y., Shen, P., Yan, Z., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0132 · Cited by 25
Luan, X., Chen, P., Li, Y., Yuan, X., Miao, L., Zhang, P., Cao, Q., Song, X., & Di, G. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03342-3 · Cited by 25
Bobyleva, P. I., Andreeva, E. R., Gornostaeva, A. N., & Buravkova, L. B. (2016) · Stem Cells International · doi:10.1155/2016/4726267 · Cited by 21
“Thus, they are now MSCs considered more to be immune evasive than immunotolerant, which may affect their functions in allogeneic applications [17].”
Buitrago, J. C., Morris, S. L., Backhaus, A., Kaltenecker, G., Kaipa, J. M., Girard, C., Schneider, S., & Gruber, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-75956-3 · Cited by 21
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Kawatani, K., Omana Suarez, G., Perkerson, R. B., Parent, E. E., Nambara, T., Knight, J. A., Parsons, T. M., Gupta, K., Shue, F., Alnobani, A., et al. (2025) · The Journal of Neuroscience · doi:10.1523/jneurosci.0606-24.2024 · Cited by 18
Development and evaluation of IL‐6 overexpressing mesenchymal stem cells (MSCs)
Huang, P., Zhang, C., Delawary, M., Korchak, J. A., Suda, K., & Zubair, A. C. (2022) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3274 · Cited by 15
Wang, X., Jin, L., Liu, W., Stingelin, L., Zhang, P., & Tan, Z. (2023) · Biomaterials Science · doi:10.1039/d3bm00346a · Cited by 15
Swain, H. N., Boyce, P. D., Bromet, B. A., Barozinksy, K., Hance, L., Shields, D., Olbricht, G. R., & Semon, J. A. (2024) · Biochimie · doi:10.1016/j.biochi.2024.04.009 · Cited by 13
Chiu, Y.-S., Wu, K.-J., Yu, S.-J., Wu, K.-L., Hsieh, C.-Y., Chou, Y.-S., Chen, K.-Y., Wang, Y.-S., Bae, E.-K., Hung, T.-W., et al. (2024) · Cell Transplantation · doi:10.1177/09636897241296366 · Cited by 10
Bi, X., Ma, B., Liu, W., Gao, W.-Q., Ye, J., & Rao, H. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04109-0 · Cited by 7
Metadata
- Authors
- Ankrum, J. A., Ong, J. F., & Karp, J. M.
- Venue
- Nature Biotechnology
- Published
- 2014-02-23
- Volume
- 32
- Issue
- 3
- Pages
- 252-260
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2038399651
- Cited by
- 1,531
- References
- 101
- FWCI
- 41.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.